- Delta-8 THC among many new strains gaining popularity with consumers in rapidly growing cannabis market
- Studies suggest optimized cannabinoid profiles play role in efficacy, strains can be optimized for recreational and medical uses
- Pac Roots leverages genetics-first approach to produce superior strains with optimized cannabinoid profiles, resistance to fungus, maximum yields
With promises of pain relief, minimal paranoia and a milder euphoric effect, Delta-8 THC is emerging as a gentler alternative to traditional marijuana that is high in Delta-9 THC – the psychoactive component found in conventional cannabis (https://ibn.fm/oABXj). Through its genetics-first cultivation approach, Pac Roots Cannabis (CSE: PACR) (OTCQB: PACRF) (FSE: 4XM), a Canadian cannabis company that leverages the power of genetic technology, is positioned favorably to capture a significant portion of the rapidly growing demand for premium cannabis products.
Strains with high concentrations of Delta-8 THC are among many new varieties of cannabis entering mainstream consumer consciousness. With varying degrees of potency, numerous textures, and distinct flavors, these emerging product lines are leveraging consumer demand for novel strains that can be used for different purposes. While still in a legal grey area, industry experts such as New Leaf Data Services CFO Ian Laird have recognized Delta-8’s potential, dubbing it as “the fastest growing segment” of hemp strains that have “really come out of nowhere over the past year.”
In accordance with the growing demand for specialized products, Pac Roots produces distinctive cannabis strains tailored for a variety of medical and recreational purposes through its exclusive partnership with Phenome One – a plant breeding management and analytics firm. The agreement sets Pac Roots apart from other producers by giving the Company access to one of Canada’s largest live genetic libraries. Comprised of over 350 unique laboratory-verified and stringently field-tested cannabis cultivars, the catalog also contains over 50 “super-elite” strains prized in the industry. Besides the ability to optimize cannabinoid profiles, Pac Roots’ partnership with Phenome One also allows the Company to produce first-in-class fungus-resistant strains that provide maximum yields – and profits.
Optimizing cannabis strains is verified science, according to recent research reports that outline how varying amounts of specific cannabinoids and other active cannabis compounds provide superior pain relief and increased control of epileptic seizures (https://ibn.fm/U6ijs). Referred to as the “entourage effect”, researchers attribute the remarkable performance of optimized cannabis to the synergistic effect of specific cannabinoids and other organic compounds found in the plant.
As the popularity of distinctive strains like Delta-8 continue to gain momentum, the need for specialized cannabis cultivation is expected to grow. With access to Phenome One’s exclusive genetic library, Pac Roots is favorably positioned to address this growing market as a leader in genetics-focused cannabis cultivation.
For more information, visit the company’s website at www.PacRoots.ca.
NOTE TO INVESTORS: The latest news and updates relating to PACR are available in the company’s newsroom at http://ibn.fm/PACR
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.